List of Excipients in Branded Drug FUROSEMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hikma Pharmaceuticals USA Inc	FUROSEMIDE	furosemide	0143-9155	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	FUROSEMIDE	furosemide	0143-9155	SODIUM CHLORIDE
Hikma Pharmaceuticals USA Inc	FUROSEMIDE	furosemide	0143-9155	SODIUM HYDROXIDE

Generic Drugs Containing FUROSEMIDE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	furosemide	0054-4297	CELLULOSE, MICROCRYSTALLINE
Hikma Pharmaceuticals USA Inc	furosemide	0054-4297	LACTOSE MONOHYDRATE
Hikma Pharmaceuticals USA Inc	furosemide	0054-4297	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in FUROSEMIDE?

# Of NDCs	Excipient
1	ALCOHOL
53	ANHYDROUS LACTOSE
62	CELLULOSE, MICROCRYSTALLINE

Furosemide Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Furosemide is a mature, low-cost loop diuretic with limited active-ingredient exclusivity and substantial formulation opportunity. Commercial value is concentrated in differentiated dosage forms, pediatric and geriatric liquids, preservative-free products, ready-to-use injection systems, combination products, and formulations that improve dose uniformity, stability, tolerability, or administration outside hospitals.

What is the commercial status of furosemide?

Furosemide is an established loop diuretic approved for edema associated with congestive heart failure, hepatic disease, renal disease, and hypertension. It is available primarily as oral tablets, oral solutions, and injectable products. Sanofi commercialized the original Lasix brand, while numerous manufacturers now supply generic furosemide products.

Attribute	Furosemide market position
Active ingredient	Furosemide
Therapeutic class	Loop diuretic
Principal routes	Oral and intravenous/intramuscular
Common strengths	Tablets: 20 mg, 40 mg, 80 mg; other strengths may be marketed
Injection strengths	Commonly 10 mg/mL
Regulatory status	Long-established FDA-approved drug
Core composition exclusivity	Expired or commercially insignificant
Generic competition	Extensive
Biosimilar risk	None; furosemide is a small molecule
Main commercial opportunity	Product differentiation rather than molecule ownership
Key formulation risks	Poor aqueous solubility, pH-dependent stability, light sensitivity, dose variability, excipient tolerability

The generic market limits pricing for conventional tablets. A differentiated product must solve a defined clinical or operational problem, such as difficulty swallowing, pediatric dosing, emergency administration, storage, preservative exposure, or hospital preparation burden.

What excipients are used in furosemide tablets?

Conventional furosemide tablets use standard solid-dose excipients. Typical functions include dilution, binding, disintegration, lubrication, glidancy, and moisture control.

Excipient category	Examples used in furosemide tablets	Primary function	Commercial consideration
Diluent	Lactose, microcrystalline cellulose, dibasic calcium phosphate	Adds bulk and supports compression	Lactose-free products can target intolerance and procurement requirements
Binder	Pregelatinized starch, povidone, hydroxypropyl cellulose	Improves tablet strength	Excessive binding can slow disintegration
Disintegrant	Corn starch, crospovidone, croscarmellose sodium, sodium starch glycolate	Promotes tablet breakup	Important for low-dose uniformity and dissolution
Glidant	Colloidal silicon dioxide	Improves powder flow	Useful in direct-compression manufacturing
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces punch and die friction	Over-lubrication can impair dissolution
Colorant	Approved iron oxides or other permitted colorants	Product identification	Relevant to light protection and brand differentiation
Film former	Hypromellose, polyvinyl alcohol	Coating and handling	Enables moisture, taste, and identification strategies

Furosemide is a low-dose active pharmaceutical ingredient in many presentations. Content uniformity is therefore a major manufacturing issue. Excipient particle-size distribution, blend segregation, electrostatic behavior, and order of addition can materially affect dose uniformity.

A direct-compression platform can reduce processing steps, but it requires consistent API morphology and powder flow. Wet granulation may improve blend uniformity and compressibility but introduces moisture and drying variables. Dry granulation may be preferable where moisture exposure threatens stability.

Which excipients improve furosemide dissolution?

Furosemide has pH-dependent aqueous solubility and is generally considered poorly soluble in its neutral form. Dissolution performance can be improved through particle engineering, wetting agents, alkalinization, solid dispersions, and lipid or amorphous systems.

Alkalinizing agents

Furosemide dissolves more readily at higher pH because of ionization. Potential formulation excipients include:

• Sodium bicarbonate
• Sodium carbonate
• Tromethamine
• Sodium citrate
• Other pharmaceutically acceptable buffering agents

The selection must account for local pH, taste, chemical stability, precipitation risk, and compatibility with packaging. An alkaline formulation can increase dissolution but may create a highly unpleasant taste in an oral liquid.

Wetting agents and surfactants

Polysorbates, poloxamers, sodium lauryl sulfate, and related surfactants may improve wetting and dissolution. Their use is constrained by:

• Taste and mouthfeel
• Oxidative degradation
• Peroxide content
• Foaming
• Injection tolerability
• Concentration-dependent gastrointestinal effects

For oral solid products, a low surfactant concentration may improve dissolution without changing the dosage form materially. For parenteral products, excipient selection is narrower because safety and route-specific tolerability are more restrictive.

Amorphous and particle-engineered systems

Commercially relevant approaches include:

• Micronized furosemide
• Nanosized furosemide
• Spray-dried amorphous dispersions
• Hot-melt or solvent-based solid dispersions
• Co-crystals
• Cyclodextrin complexes
• Self-emulsifying or lipid-based systems

These approaches may create formulation patents if the composition, process, particle attributes, or performance is sufficiently distinct. They also increase development cost and may trigger additional characterization of crystallinity, recrystallization, dissolution, and bioequivalence.

What excipients are used in furosemide oral solutions?

Oral solutions address swallowing difficulty and allow weight-based dosing. They create commercial opportunities in pediatrics, long-term care, home care, and patients with feeding tubes.

Typical excipient functions include:

Function	Potential excipient classes
Solubilization	pH adjusters, cosolvents, surfactants, complexing agents
Sweetening	Sucrose, sorbitol, sucralose, saccharin sodium
Viscosity control	Glycerin, propylene glycol, hydroxyethyl cellulose
Preservation	Methylparaben, propylparaben, benzoates, sorbates
Flavoring	Fruit, vanilla, or other pharmaceutical flavors
Buffering	Citrate, phosphate, carbonate, or tromethamine systems
Chelation	Disodium edetate where justified
Antioxidation	Sulfite-based or other systems where compatible

The main formulation challenge is balancing solubility with palatability. A high-pH solution may support furosemide solubility but produce a bitter or alkaline taste. Sweeteners and flavors can mask taste but may create sugar, dental, metabolic, or excipient-sensitivity concerns.

A sugar-free, alcohol-free, dye-free, preservative-free, or low-osmolality oral solution can support premium positioning. Products intended for feeding tubes should be evaluated for sedimentation, adsorption, tube compatibility, flush volumes, and administration-device accuracy.

What excipients are used in furosemide injection?

Furosemide injection is generally formulated as an alkaline aqueous solution. Commercial products commonly use sodium hydroxide for pH adjustment, sodium chloride for tonicity, and water for injection. Product labels specify pH, concentration, storage, and light-protection requirements. [1-3]

Key parenteral formulation considerations include:

• pH control and buffer capacity
• Prevention of precipitation after dilution
• Compatibility with infusion fluids
• Container closure adsorption
• Light protection
• Sterility assurance
• Endotoxin control
• Particulate matter
• Low extractables and leachables
• Compatibility with syringes, bags, and administration sets

Furosemide injection is particularly sensitive to formulation pH and compatibility conditions. Mixing with acidic solutions can cause precipitation. A ready-to-administer or pharmacy-ready presentation could reduce preparation errors, but it would require robust compatibility and stability data.

Commercial parenteral opportunities

Potential products include:

1. Ready-to-use prefilled syringes for emergency departments, intensive care units, and ambulances.
2. Small-volume bags that eliminate bedside dilution.
3. Preservative-free single-dose containers for high-risk hospital use.
4. Stable concentrated presentations for institutional pharmacy preparation.
5. Light-protective packaging systems with validated in-use stability.
6. Dose-banded products for common adult dosing protocols.

The commercial case depends on reducing medication-preparation labor, waste, dosing errors, and inventory complexity. A price premium is more credible for hospital workflow products than for conventional multidose vials.

What formulation patents could protect furosemide products?

Furosemide’s active ingredient is old and widely generic. New patent value would generally arise from a specific formulation, manufacturing process, delivery system, or method of use rather than from furosemide itself.

Formulation patent targets

Potentially protectable subject matter includes:

• A defined furosemide particle-size distribution
• A specific polymorph or amorphous form
• A solid dispersion with a named polymer
• A buffered solution within a defined pH range
• A preservative-free liquid with defined stability
• A taste-masked multiparticulate dosage form
• A formulation compatible with enteral feeding tubes
• A controlled-release oral dosage form
• A ready-to-use injectable composition
• A prefilled syringe or infusion container
• A specific excipient ratio that improves dissolution or stability
• A manufacturing process that produces a defined impurity profile

Patent strength depends on claim breadth, reproducibility, prior-art distance, and the ability to demonstrate an unexpected technical effect. A claim covering only routine excipient substitution is vulnerable. A formulation with comparative dissolution, stability, bioavailability, or usability data has a stronger enforcement position.

Method-of-use patents

Potential method-of-use opportunities are narrower because furosemide has broad and long-established indications. Potentially differentiated areas could include:

• Specific dosing regimens for acute decompensated heart failure
• Administration protocols based on renal function or prior diuretic exposure
• Combination use with another diuretic or cardiovascular agent
• Pediatric or neonatal dosing
• Enteral administration protocols
• Use in a defined patient subgroup with pharmacokinetic or clinical criteria

Method claims face practical enforcement challenges when the product is prescribed for multiple established indications.

When does furosemide lose exclusivity?

Furosemide lost meaningful market exclusivity decades ago. The FDA Orange Book lists approved products, therapeutic-equivalence evaluations, patent certifications, and certain exclusivity information, but the current commercial position is one of extensive generic availability rather than protected brand exclusivity. [4]

Exclusivity category	Current relevance to furosemide
New chemical entity exclusivity	Expired
Core composition patent	Expired
Conventional tablet exclusivity	Expired
Conventional injection exclusivity	Expired
Biosimilar exclusivity	Not applicable
Pediatric exclusivity	Not a current market barrier for ordinary products
New formulation exclusivity	Possible only for a qualifying new product
New clinical investigation exclusivity	Potentially available in limited regulatory circumstances

A new furosemide formulation could receive three-year FDA exclusivity for qualifying new clinical investigations supporting approval of a change, subject to statutory requirements. A new drug application may also obtain five-year new chemical entity exclusivity only where the active moiety qualifies as a new chemical entity, which furosemide does not. [5]

What is the Orange Book and Paragraph IV status of furosemide?

The principal legal risk for a conventional furosemide product is not originator patent litigation. It is competition from established ANDA holders and possible infringement disputes involving a differentiated formulation.

A generic applicant may file an ANDA with:

• Paragraph I certification when no patent information is listed
• Paragraph II certification when a patent has expired
• Paragraph III certification when the applicant waits for patent expiration
• Paragraph IV certification when the applicant asserts that a listed patent is invalid, unenforceable, or not infringed

For a new furosemide formulation, an applicant could face Paragraph IV litigation if the reference listed drug has relevant formulation or method-of-use patents. A formulation developer can reduce risk by conducting a claim-by-claim freedom-to-operate review covering:

• Orange Book-listed patents
• Continuation and divisional applications
• Non-Orange-Book formulation patents
• Device and container patents
• Manufacturing-process patents
• Use patents
• Patent term adjustments and extensions
• Settlement agreements and launch restrictions

No biosimilar pathway applies because furosemide is a chemically synthesized small molecule. The relevant regulatory routes are generally ANDA, 505(b)(2), or, in less common circumstances, a full 505(b)(1) NDA. A 505(b)(2) strategy may be appropriate for a novel liquid, injectable presentation, delivery system, or clinical use supported partly by existing literature or FDA findings for an approved product. [5-7]

How strong is the patent estate for furosemide?

The core furosemide patent estate is weak from a commercial exclusivity perspective because the molecule and conventional dosage forms are mature. A new formulation estate can be stronger if it has:

• Narrow but technically meaningful composition claims
• Process claims tied to a reproducible product attribute
• Multiple independent claim categories
• Human pharmacokinetic or clinical evidence
• Improved stability under labeled storage conditions
• A meaningful dosing or administration advantage
• Claims covering both composition and commercial packaging

A single broad excipient claim is unlikely to provide durable protection. A layered estate could include composition, particle attributes, manufacturing process, dosage form, container closure, and method-of-use claims.

Which furosemide products have the strongest commercial opportunity?

Product concept	Target customer	Differentiation	Likely regulatory route	Commercial outlook
Sugar-free oral solution	Pediatric, geriatric, diabetic, long-term care	Dosing flexibility and swallowability	ANDA or 505(b)(2)	Moderate
Alcohol-free and preservative-free liquid	Pediatric and chronic-use patients	Excipient reduction	ANDA or 505(b)(2)	Moderate
Enteral-tube-compatible solution	Hospitals and home care	Administration reliability	505(b)(2) or ANDA	Moderate to high
Taste-masked granules	Pediatrics and dysphagia	Improved adherence	505(b)(2)	Moderate
Orally disintegrating tablet	Dysphagia and acute outpatient use	No-water administration	505(b)(2) or ANDA	Moderate
Extended-release tablet	Chronic edema and hypertension	Reduced dosing frequency	505(b)(2)	High development risk
Prefilled injection	Hospitals and emergency care	Workflow and dosing efficiency	505(b)(2) or NDA	High institutional potential
Ready-to-use infusion bag	Intensive care and emergency care	Reduces preparation steps	505(b)(2) or NDA	High but operationally complex
Micronized or amorphous product	Generic and specialty markets	Dissolution or exposure improvement	ANDA or 505(b)(2)	Depends on clinical advantage
Combination diuretic product	Heart failure or resistant edema	Regimen simplification	505(b)(2)	Potentially attractive

The strongest opportunities are products with a clear buyer and measurable economic benefit. Hospital-ready injectable products can command a premium if they reduce preparation time and medication errors. Pediatric and enteral products can support differentiated pricing where current options are difficult to administer.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are more important than raw-material availability. Furosemide is widely manufactured, but differentiated products may require:

• Controlled API particle engineering
• Low-shear blending to limit segregation
• Moisture-controlled granulation
• Validated pH adjustment
• Aseptic filling
• Light-protective container systems
• Low-particulate processing
• Extractables and leachables studies
• Long-term and accelerated stability programs
• Specialized filling or dose-delivery equipment

For oral liquids, the critical control strategy includes assay, degradation products, microbial quality, viscosity, pH, delivered dose, preservative effectiveness where applicable, and in-use stability.

For injections, the control strategy includes sterility, endotoxins, particulate matter, pH, assay, impurities, container closure integrity, dilution compatibility, and precipitation after administration. FDA’s guidance on inactive ingredients and ICH quality guidelines provide the applicable framework for excipient qualification and product development. [7-9]

How does furosemide compare with competing loop diuretics?

Drug	Relative formulation position	Commercial implication
Furosemide	Lowest-cost, broadest generic availability	Differentiation must come from delivery or workflow
Torsemide	Oral loop diuretic with longer duration and favorable absorption characteristics	Competes on chronic heart-failure convenience
Bumetanide	Potent loop diuretic available in oral and injectable forms	Competes in dose flexibility and potency
Ethacrynic acid	Non-sulfonamide loop diuretic	Niche use where sulfonamide concerns affect selection

Furosemide’s advantage is market familiarity, low acquisition cost, and extensive clinical experience. Its disadvantages include variable oral absorption, short duration, and formulation sensitivity. A new excipient strategy should target one of those disadvantages rather than replicate an existing immediate-release tablet.

What licensing and partnership opportunities exist?

Licensing value is most credible in four areas:

1. Hospital injectable platforms: A developer with ready-to-use sterile filling, prefilled syringe, or infusion-bag capabilities could partner with a generic manufacturer.
2. Pediatric and enteral formulations: A company with taste-masking, tube-compatibility, or liquid-dose technology could license a platform to a specialty pharmaceutical partner.
3. Particle-engineered furosemide: A formulation owner could license a composition and manufacturing process to an ANDA or 505(b)(2) sponsor.
4. Combination products: A cardiovascular company could combine furosemide with complementary antihypertensive or heart-failure therapy, subject to clinical and patent review.

Licensing negotiations should value the product’s regulatory pathway, formulation reproducibility, patent term, manufacturing complexity, reimbursement position, and switching barriers. A formulation with no clinical or operational benefit will face rapid generic price competition.

What generic launch risks exist for a new furosemide product?

The principal risks are:

• Rapid substitution by low-cost tablets
• Limited payer willingness to reimburse a premium
• Failure to demonstrate bioequivalence
• Precipitation or instability in liquid or injectable products
• Poor taste and low adherence
• Device or container compatibility failures
• Narrow patent claims
• Development of a competing formulation before launch
• Hospital procurement resistance
• Inadequate evidence for a 505(b)(2) clinical bridge

A successful launch should use a specific positioning claim, such as "preservative-free pediatric oral solution," "ready-to-administer emergency injection," or "enteral-tube-compatible formulation." General claims of improved convenience are less defensible commercially.

Key Takeaways

• Furosemide has no meaningful core-molecule exclusivity and faces extensive generic competition.
• Excipient strategy is most valuable in oral liquids, pediatric products, enteral formulations, and hospital injectables.
• Alkalinization can improve solubility but creates taste, stability, and precipitation challenges.
• Conventional tablet excipients offer limited differentiation unless linked to dissolution, uniformity, stability, or manufacturing advantages.
• The strongest patent opportunities involve defined compositions, particle attributes, processes, delivery systems, and clinically relevant use claims.
• Biosimilar risk is irrelevant because furosemide is a small molecule.
• The most attractive commercial opportunities are ready-to-use injectable systems and patient-friendly liquid formulations.
• A 505(b)(2) pathway may be suitable for novel dosage forms, while conventional generics generally use the ANDA route.
• Commercial success depends on solving a specific administration or workflow problem, not on the intrinsic value of the furosemide molecule.

FAQs

Can furosemide be formulated as a preservative-free oral liquid?

Yes. A preservative-free formulation is technically feasible, but it requires validated microbial-control measures, packaging, in-use stability, and multidose-use instructions.

Which excipient is best for improving furosemide solubility?

No single excipient is universally optimal. Alkalinizing agents, surfactants, cyclodextrins, and solid-dispersion polymers each address solubility through different mechanisms and create different stability and tolerability risks.

Is a furosemide oral solution eligible for a new patent?

Potentially. Patentability may arise from a novel composition, pH range, excipient combination, taste-masking system, stability profile, packaging system, or manufacturing process, subject to prior-art and claim-scope analysis.

Can furosemide be developed as an extended-release product?

Yes, but the development burden is high. The product must control release while preserving reliable diuretic exposure and avoiding delayed or inadequate diuresis in patients requiring prompt treatment.

What is the most defensible premium furosemide product?

A ready-to-administer sterile injectable or a well-characterized pediatric and enteral oral liquid generally has a stronger premium rationale than another conventional tablet.

References

1. U.S. Food and Drug Administration. (n.d.). DailyMed: Furosemide injection labeling. National Library of Medicine.
2. U.S. Food and Drug Administration. (n.d.). DailyMed: Furosemide tablet labeling. National Library of Medicine.
3. U.S. Food and Drug Administration. (n.d.). DailyMed: Furosemide oral solution labeling. National Library of Medicine.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.
6. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2).
7. U.S. Food and Drug Administration. (2019). Determining whether to submit an ANDA or a 505(b)(2) application.
8. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development.
9. International Council for Harmonisation. (2023). Q3C(R8): Impurities: Guideline for residual solvents.